Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: JJINV who wrote (53423)	12/12/2019 12:30:46 PM
From: erippetoe	6 Recommendations Recommended By bobbseytwins2001 captcobra1 idahoranch1 JJINV KeeptheFaith and 1 more member Read Replies (1) \| Respond to of 63324

4 deaths from ILD, doesn't sound good IMO

To: JJINV who wrote (53423)	12/12/2019 8:23:56 PM
From: trickydick	Read Replies (1) \| Respond to of 63324

JJINV I can understand most of this material, but, since there's so many other treatments in various stages of development for treating certain types of cancer, I need a little help, if you can. I don't have the knowledge or experience to see the big picture, so my question is: For this trial you presented, how does it affect 132 and any other products that are in various stages of development by IMMU? If 132's submission is approved as submitted and approved soon, does that give IMMU a step ahead of the competition for a product that has better trial results? Trying to be a better informed investor. Thank you in advance.